Literature DB >> 6136310

Do beta-adrenoceptor blocking drugs cause retroperitoneal fibrosis?

J P Pryor, W M Castle, D C Dukes, J C Smith, M E Watson, J L Williams.   

Abstract

The aetiology of retroperitoneal fibrosis is unknown. From time to time different drugs have been suggested as a cause, including beta adrenoceptor blocking agents. The notes of 100 hospital inpatients in whom retroperitoneal fibrosis had been diagnosed were surveyed to identify the date of onset of symptoms, the drugs prescribed before then, and the blood pressures on admission. Seventy one patients had diastolic pressures on admission of 90 mm Hg or more and 53 of these had pressures of at least 100 mm Hg despite 14 of the patients taking anti-hypertensive drugs at the time. Six patients had received beta-adrenoceptor blocking agents before the onset of symptoms and a further 24 received them subsequently. In particular, three patients continued treatment for at least six years after the diagnosis was made and surgery performed, without suffering a recurrence of retroperitoneal fibrosis. Besides beta-adrenoceptor drugs, diuretics and other hypotensive drugs were taken in amounts reflecting the pattern of drug use among hypertensive patients generally. Rather than being causal agents, the antihypertensive drugs were probably being used to treat hypertension associated with the retroperitoneal fibrosis, and our findings suggest that beta-adrenoceptor blocking agents do not cause retroperitoneal fibrosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136310      PMCID: PMC1548788          DOI: 10.1136/bmj.287.6393.639

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  23 in total

1.  Analgesic abuse, ureteric obstruction, and retroperitoneal fibrosis.

Authors:  C T Lewis; E A Molland; V R Marshall; G C Tresidder; J P Blandy
Journal:  Br Med J       Date:  1975-04-12

2.  Adverse effects of practolol.

Authors:  J T Nicholls
Journal:  Ann Clin Res       Date:  1976-08

3.  Atenolol in hypertension a study of long-term therapy.

Authors:  F J Zacharias; K J Cowen; P F Cuthbertson; T B Johnson; J Prestt; J Thompson; J Vickers; W T Simpson; R Tuson
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Slow-Trasicor (sustained-release oxprenolol hydrochloride 160 mg) in the treatment of essential hypertension: a multicentre evaluation of 4,400 patients.

Authors:  W A Forrest
Journal:  Br J Clin Pract       Date:  1977-11

5.  Retroperitoneal fibrosis and ergot derivatives.

Authors:  J F Stecker; H P Rawls; C J Devine; P C Devine
Journal:  J Urol       Date:  1974-07       Impact factor: 7.450

6.  Retroperitoneal fibrosis: an analysis of the clinical spectrum and roentgenographic signs.

Authors:  P H Arger; J L Stolz; W T Miller
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1973-12

7.  The pathology of idiopathic retroperitoneal fibrosis.

Authors:  M J Mitchinson
Journal:  J Clin Pathol       Date:  1970-11       Impact factor: 3.411

8.  Retroperitoneal fibrosis. A radiological and follow-up study of fourteen cases.

Authors:  H M Saxton; F R Kilpatrick; C H Kinder; M H Lessof; S McHardy-Young; D F Wardle
Journal:  Q J Med       Date:  1969-04

9.  Retroperitoneal fibrosis during treatment with methydopa.

Authors:  B M Iversen; J W Johannesen; E Nordahl; J Ofstad; S Thunold; Y Willassen
Journal:  Lancet       Date:  1975-08-16       Impact factor: 79.321

10.  The clinical significance of retroperitoneal fibrosis.

Authors:  L Koep; G D Zuidema
Journal:  Surgery       Date:  1977-03       Impact factor: 3.982

View more
  8 in total

Review 1.  Chronic periaortitis--a new interpretation of Ormond's disease.

Authors:  B Martina
Journal:  Urol Res       Date:  1990

2.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

3.  Weber-Christian disease producing splenic vein occlusion and bleeding gastric varices: successful treatment with sclerotherapy.

Authors:  D Heseltine; M Bramble; A Cole; D Clarke; W Castle
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

Review 4.  Idiopathic retroperitoneal fibrosis.

Authors:  N Bullock
Journal:  BMJ       Date:  1988-07-23

Review 5.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

6.  Serum IgG4 Concentration Is a Potential Predictive Biomarker in Glucocorticoid Treatment for Idiopathic Retroperitoneal Fibrosis.

Authors:  Shoichiro Mukai; Naotaka Sakamoto; Hiroaki Kakinoki; Tadamasa Shibuya; Ryosuke Moriya; Kiyoaki Nishihara; Mitsuru Noguchi; Toshitaka Shin; Naohiro Fujimoto; Tsukasa Igawa; Tatsu Ishii; Nobuhiro Haga; Hideki Enokida; Masatoshi Eto; Tomomi Kamba; Hideki Sakai; Seiichi Saito; Naoki Terada; Toshiyuki Kamoto
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

7.  Retroperitoneal fibrosis, hypercholestrolaemia and acute myocardial infarction.

Authors:  P A Routledge
Journal:  J R Soc Med       Date:  1990-05       Impact factor: 18.000

8.  Retroperitoneal fibrosis associated with propranolol: a case report; is corticosteroid administration necessary after ureterolysis?

Authors:  Majid Shirani; Azadeh Davoudian; Abolghasem Sharifi
Journal:  J Renal Inj Prev       Date:  2013-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.